Altered gut microbiota composition with antibiotic treatment impairs functional recovery after traumatic peripheral nerve crush injury in mice: effects of probiotics with butyrate producing bacteria.
16S rRNA analysis
Antibiotics
Functional recovery
Gut microbiota
Peripheral nerve injury
Probiotics
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
23 Feb 2022
23 Feb 2022
Historique:
received:
08
12
2021
accepted:
09
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Antibiotics (ABX) are widely used for life-threatening infections and also for routine surgical operations. Compelling evidence suggests that ABX-induced alterations of gut microbiota composition, termed dysbiosis, are linked with diverse disease states including neurological and neurodegenerative conditions. To combat the consequences of dysbiosis, probiotics (PBX) are widely used. ABX-induced dysbiosis is reported to impair neurological function after spinal cord injury. Traumatic peripheral nerve injury (TPNI) results in profound neurologic impairment and permanent disability. It is unknown whether ABX treatment-induced dysbiosis has any impact on TPNI-induced functional recovery, and if so, what role medical-grade PBX could have on TPNI recovery. In this study, ABX-induced dysbiosis and PBX-induced microbiota enrichment models were used to explore the potential role of gut microbiome in TPNI. Stool analysis with 16S ribosomal RNA (rRNA) gene sequencing confirmed ABX-induced dysbiosis and revealed that ABX-induced changes could be partially restored by PBX administration with an abundance of butyrate producing bacteria. Pre-injury ABX significantly impaired, but pre-injury PBX significantly improved post-TPNI functional recovery. Importantly, post-injury PBX protected against pre-injury ABX-induced functional impairment. These findings demonstrate that reestablishment of gut microbiota composition with butyrate producing PBX during ABX-induced dysbiosis could be a useful adjuvant therapy for TPNI.
Identifiants
pubmed: 35197129
doi: 10.1186/s13104-022-05967-8
pii: 10.1186/s13104-022-05967-8
pmc: PMC8867741
doi:
Substances chimiques
Anti-Bacterial Agents
0
Butyrates
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Subventions
Organisme : NIH HHS
ID : K08 AR060164-01A
Pays : United States
Organisme : U.S. Department of Defense
ID : W81XWH-16-1-0725
Informations de copyright
© 2022. The Author(s).
Références
Evol Bioinform Online. 2007 Feb 17;2:121-8
pubmed: 19455206
Pharmacol Ther. 2016 Feb;158:52-62
pubmed: 26627987
Plast Reconstr Surg. 1989 Jan;83(1):129-38
pubmed: 2909054
Infect Immun. 2009 Jun;77(6):2367-75
pubmed: 19307217
J Neurosci Methods. 2001 Jul 15;108(1):1-9
pubmed: 11459612
J Bone Joint Surg Am. 2008 Aug;90(8):1644-53
pubmed: 18676893
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
mSystems. 2015 Dec 22;1(1):
pubmed: 27822518
Cell Immunol. 2019 May;339:50-58
pubmed: 30366573
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
ISME J. 2007 May;1(1):56-66
pubmed: 18043614
Br J Nutr. 2014 Feb;111(3):387-402
pubmed: 23931069
Exp Ther Med. 2019 Sep;18(3):2262-2270
pubmed: 31452713
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Am J Pathol. 2018 Dec;188(12):2786-2799
pubmed: 30470496
World J Clin Cases. 2020 Apr 26;8(8):1361-1384
pubmed: 32368530
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4554-61
pubmed: 20847294
Mil Med. 2021 Jan 25;186(Suppl 1):473-478
pubmed: 33499447
Global Spine J. 2020 Jan;10(1 Suppl):92S-98S
pubmed: 31934527
Neurotherapeutics. 2018 Jan;15(1):23-30
pubmed: 29313275
Gut. 2015 Nov;64(11):1732-43
pubmed: 25614621
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
Drugs. 2006;66(10):1371-87
pubmed: 16903771
Nat Rev Microbiol. 2021 Apr;19(4):241-255
pubmed: 33093662
J Investig Med High Impact Case Rep. 2014 Jul 27;2(3):2324709614545225
pubmed: 26425618
J Neurosci Res. 2020 May;98(5):780-795
pubmed: 31608497
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
J Exp Med. 2016 Nov 14;213(12):2603-2620
pubmed: 27810921
Acta Neuropathol. 2015 Nov;130(5):605-18
pubmed: 26419777
Gut Microbes. 2016 May 3;7(3):189-200
pubmed: 26963409
Curr Opin Microbiol. 2019 Oct;51:72-80
pubmed: 31733401
Int Immunol. 2020 Sep 30;32(10):629-636
pubmed: 32564086
Gut. 2016 Nov;65(11):1906-1915
pubmed: 27531828
Hand (N Y). 2018 May;13(3):259-263
pubmed: 28347178
Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):637-642
pubmed: 29566906
Nat Neurosci. 2015 Jul;18(7):965-77
pubmed: 26030851
Nat Rev Immunol. 2013 May;13(5):321-35
pubmed: 23618829
Nature. 2012 Aug 30;488(7413):621-6
pubmed: 22914093
Front Cell Infect Microbiol. 2017 May 05;7:167
pubmed: 28529928
Microorganisms. 2018 Apr 25;6(2):
pubmed: 29693607
J Neuroinflammation. 2019 Jun 27;16(1):129
pubmed: 31248424
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Biosci Biotechnol Biochem. 2020 Feb;84(2):411-420
pubmed: 31661358
Biochem Pharmacol. 2017 Jun 1;133:4-19
pubmed: 27720719
Appl Environ Microbiol. 2007 Mar;73(5):1576-85
pubmed: 17220268
FEBS Lett. 2014 Nov 17;588(22):4120-30
pubmed: 24681100
Infect Immun. 2012 Jan;80(1):62-73
pubmed: 22006564
Dig Dis. 1998 Sep-Oct;16(5):292-307
pubmed: 9892789
Cell Mol Life Sci. 2017 Oct;74(20):3769-3787
pubmed: 28643167
Front Physiol. 2011 Dec 07;2:94
pubmed: 22162969
BMJ. 2002 Jun 8;324(7350):1345-6
pubmed: 12052785
JAMA. 2012 May 9;307(18):1959-69
pubmed: 22570464
Int Rev Neurobiol. 2013;108:173-206
pubmed: 24083435
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
J Hand Surg Am. 2018 May;43(5):407-416.e1
pubmed: 29398330
Cell Rep. 2016 May 31;15(9):1945-56
pubmed: 27210745